GlassScriptPhysician profile
Dmitriy Buyanov
NPI 1124047261
$1,475.19
in general payments reported to CMS, 2019-2025
23 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $139 · 2021: $153 · 2022: $220 · 2023: $148 · 2024: $231 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $343.42 | 2019-2025 | Xtampza, Belbuca |
| Globus Medical, INC. | $170.49 | 2025 | Senza |
| Medtronic USA, INC. | $131.43 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.72 | 2022-2024 | Relistor |
| Medtronic, INC. | $106.99 | 2021-2025 | Inceptiv, Intellis Adaptivestim |
| Abbott Laboratories | $79.88 | 2023 | Proclaim |
| Averitas Pharma INC. | $76.24 | 2024-2025 | Qutenza |
| Pfizer INC. | $55.61 | 2019-2020 | |
| Forte Bio-Pharma LLC | $52.26 | 2021 | |
| Hikma Pharmaceuticals USA | $50.91 | 2022 | |
| Protega Pharmaceutials INC | $44.32 | 2025 | Roxybond |
| Si-Bone, INC. | $40.00 | 2019-2024 | |
| Vertos Medical, INC. | $26.90 | 2020 | |
| Ibsa Pharma INC. | $25.99 | 2021-2023 | Tirosint, Licart |
| Azurity Pharmaceuticals, INC. | $23.69 | 2024 | Horizant |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $23.25 | 2025 | Triluron, Hymovis |
| Grt US Holding, INC. | $23.22 | 2022 | |
| Valinor Pharma, LLC | $21.47 | 2025 | Movantik |
| Pacira Therapeutics, INC. | $14.09 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.84 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.45 | 2022 | |
| Scilex Pharmaceuticals INC. | $12.79 | 2020 | |
| Biodelivery Sciences International, INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Buyanov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.